Ridgetech Unveils Dual-Engine Growth Strategy for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy RDGT?
Source: Newsfilter
- Supply Chain Integration Strategy: Ridgetech plans to achieve dual breakthroughs in business model innovation and value creation in 2026 by integrating its wholesale distribution network and B2B platform, thereby strengthening its long-term growth foundation in China's pharmaceutical and healthcare supply chain.
- Core Business Enhancement: The company aims to further enhance the competitiveness of its wholesale business by deepening strategic cooperation with core suppliers and expanding distribution coverage of high-margin brands, which is expected to accelerate its transformation from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Ridgetech's wholly-owned subsidiary Allright will serve as the core digital engine, targeting to expand its customer base to 300,000, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate in 2026.
- Synergistic Dual-Engine Effects: Ridgetech plans to systematically introduce Jiuxin Medicine's supply chain products onto the Allright platform, optimizing procurement and sales processes to enhance operational agility, thereby establishing a virtuous cycle where
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDGT
About RDGT
Ridgetech Inc, formerly China Jo-Jo Drugstores Inc, is a retailer and distributor of pharmaceutical and other healthcare products. The Company operates in four business segments. The Retail Drugstores segment sells prescription and over the counter (OTC) medicines, traditional Chinese medicine (TCM), dietary supplements, medical devices, and sundry items to retail customers. The Online Pharmacy segment sells OTC drugs, dietary supplements, medical devices and sundry items through its own and third-party platforms. The Wholesale Business segment includes supplying the Company's own retail drugstores and selling them to other drug vendors and hospitals. The Farming and Selling Herbs segment cultivates selected herbs for sales to other drug vendors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to enhance its competitiveness in China's pharmaceutical and healthcare market by integrating its wholesale distribution network and B2B platform, which is expected to accelerate the transition from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Subsidiary Allright will serve as the core digital engine, aiming to expand its customer base to 300,000 in 2026, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate, further enhancing market influence.
- Synergistic Dual-Engine Effects: Ridgetech will integrate its offline wholesale platform Jiuxin Medicine with Allright to optimize procurement and sales processes, improving response speed and operational agility, thereby achieving higher turnover efficiency.
- Management Strategic Outlook: CEO Frank Zhao stated that the company is committed to achieving its 2026 and medium- to long-term strategic objectives through a clear strategic roadmap and an open collaborative framework, driving high-quality development and enhancing market position.
See More
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to achieve dual breakthroughs in business model innovation and value creation in 2026 by integrating its wholesale distribution network and B2B platform, thereby strengthening its long-term growth foundation in China's pharmaceutical and healthcare supply chain.
- Core Business Enhancement: The company aims to further enhance the competitiveness of its wholesale business by deepening strategic cooperation with core suppliers and expanding distribution coverage of high-margin brands, which is expected to accelerate its transformation from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Ridgetech's wholly-owned subsidiary Allright will serve as the core digital engine, targeting to expand its customer base to 300,000, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate in 2026.
- Synergistic Dual-Engine Effects: Ridgetech plans to systematically introduce Jiuxin Medicine's supply chain products onto the Allright platform, optimizing procurement and sales processes to enhance operational agility, thereby establishing a virtuous cycle where
See More
Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results
Financial Performance Overview: Ridgetech, Inc. reported stable revenue of approximately $120 million for the fiscal year ending March 31, 2025, despite a 3.2% decrease from the previous year. The company achieved a net income of $10.20 million, a significant turnaround from a net loss of $4.23 million in the prior year.
Strategic Business Transformation: The company underwent significant changes, including divesting its retail pharmacy business and acquiring Ridgeline and Allright to enhance its wholesale distribution capabilities in both online and offline markets, reflecting a strategic shift towards the wholesale pharmaceutical sector amidst increasing competition in China's healthcare industry.
See More
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to enhance its competitiveness in China's pharmaceutical and healthcare market by integrating its wholesale distribution network and B2B platform, which is expected to accelerate the transition from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Subsidiary Allright will serve as the core digital engine, aiming to expand its customer base to 300,000 in 2026, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate, further enhancing market influence.
- Synergistic Dual-Engine Effects: Ridgetech will integrate its offline wholesale platform Jiuxin Medicine with Allright to optimize procurement and sales processes, improving response speed and operational agility, thereby achieving higher turnover efficiency.
- Management Strategic Outlook: CEO Frank Zhao stated that the company is committed to achieving its 2026 and medium- to long-term strategic objectives through a clear strategic roadmap and an open collaborative framework, driving high-quality development and enhancing market position.
See More
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to achieve dual breakthroughs in business model innovation and value creation in 2026 by integrating its wholesale distribution network and B2B platform, thereby strengthening its long-term growth foundation in China's pharmaceutical and healthcare supply chain.
- Core Business Enhancement: The company aims to further enhance the competitiveness of its wholesale business by deepening strategic cooperation with core suppliers and expanding distribution coverage of high-margin brands, which is expected to accelerate its transformation from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Ridgetech's wholly-owned subsidiary Allright will serve as the core digital engine, targeting to expand its customer base to 300,000, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate in 2026.
- Synergistic Dual-Engine Effects: Ridgetech plans to systematically introduce Jiuxin Medicine's supply chain products onto the Allright platform, optimizing procurement and sales processes to enhance operational agility, thereby establishing a virtuous cycle where
See More
Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results
Financial Performance Overview: Ridgetech, Inc. reported stable revenue of approximately $120 million for the fiscal year ending March 31, 2025, despite a 3.2% decrease from the previous year. The company achieved a net income of $10.20 million, a significant turnaround from a net loss of $4.23 million in the prior year.
Strategic Business Transformation: The company underwent significant changes, including divesting its retail pharmacy business and acquiring Ridgeline and Allright to enhance its wholesale distribution capabilities in both online and offline markets, reflecting a strategic shift towards the wholesale pharmaceutical sector amidst increasing competition in China's healthcare industry.
See More
